CDH2 and synovial sarcoma: Laskin et al. [24] described that N-cadherin was observed in chordoma (100%), biphasic synovial sarcoma (86%), diffuse mesothelioma (70%), malignant melanoma (56%), epithelioid sarcoma (38%), epithelioid angiosarcoma (25%), poorly differentiated synovial sarcoma (15%), clear cell sarcoma (10%), and monophasic fibrous synovial sarcoma (4%).